Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

US FDA Welcomes Variety Of Phase II/III Trial Designs For COVID-19 Therapies, But With Standards

May 14 2020

• By Bridget Silverman

Virus vaccine and flu or coronavirus medical fight disease control as a doctor fighting a group of contagious pathogen cells as health care for researching a cure with 3D illustration elements.

Related Content

COVID-19 Phase III Trial Design: Big Ambitions, Little Consistency

May 11 2020

US FDA Sets Convalescent Plasma Access Recommendations For Coronavirus Patients

Apr 16 2020

NIH Partnership To Pick COVID-19 Therapeutics For Clinical Trials; Results Anticipated By Summer

Apr 19 2020

NIH Pushes Ahead With First COVID-19 Combo: Remdesivir Plus Lilly’s Olumiant

May 12 2020

COVID-19 Study Of Gilead’s Remdesivir Using Ebola-Style Adaptive Platform Trial

Mar 17 2020

Related Companies

Gilead Sciences, Inc.

Eli Lilly and Company

Additional Topics

United States Clinical Trials Guidance Documents Research & Development Regulation Drug Approval Standards Infectious Diseases BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window